Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events

Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%

Hackett projects Q3 2026 adjusted EPS of $0.37-$0.39 as AI platform wins ramp

AMD expects Q3 2026 revenue of about $13B as it targets data center segment revenue to more than double in 2027

DaVita signals 2026 midpoint guidance of $2.2B adjusted operating income and $14.65 EPS while planning expanded HD rollout